Lexicon Pharmaceuticals, Inc. (LXRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Lexicon Pharmaceuticals, Inc. (LXRX) Healthcare & Pipeline Overview

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company specializing in orally-delivered small molecule drugs, including Sotagliflozin for heart failure and type 1 diabetes, and LX9211 for neuropathic pain. With strategic collaborations and a focus on innovative therapies, Lexicon operates within the competitive biotechnology sector.

What Is the Investment Thesis for LXRX?

Sotagliflozin, targeting heart failure and type 1 diabetes, represents a significant market opportunity, especially if approved for both indications. Positive Phase III trial results support its potential. LX9211, addressing neuropathic pain, offers another avenue for growth, with Phase II data providing early validation. Key value drivers include successful regulatory approvals for Sotagliflozin and LX9211, expansion of existing partnerships, and the advancement of new drug candidates. The company's gross margin of 99.1% indicates strong pricing power. However, the company's negative profit margin of -37.5% indicates that the company is not yet profitable. Upcoming FDA decisions regarding Sotagliflozin will be critical catalysts. Potential risks include clinical trial failures, regulatory setbacks, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

LXRX Key Highlights

Market capitalization of $897M reflects investor valuation of Lexicon's pipeline and potential.

• Gross margin of 99.1% demonstrates strong pricing power for its pharmaceutical products.
• Profit margin of -37.5% indicates ongoing investment in research and development, typical for a biotechnology company.
• Beta of 0.95 suggests the stock's volatility is similar to the overall market.
• Strategic collaborations with Bristol-Myers Squibb and Genentech provide financial and developmental support.

Who Are LXRX's Competitors?

LXRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LXRX's Key Strengths?

Innovative drug discovery platform.

• Promising pipeline of drug candidates.
• Strategic collaborations with major pharmaceutical companies.
• Strong intellectual property protection.

What Are LXRX's Weaknesses?

Limited commercial infrastructure.

• Reliance on partnerships for funding and development.
• Negative profit margin.
• Dependence on regulatory approvals.

What Could Drive LXRX Stock Higher?

FDA decision on Sotagliflozin for heart failure.

• FDA decision on Sotagliflozin for type 1 diabetes.
• Phase II clinical trial results for LX9211 in neuropathic pain.
• Potential for new strategic partnerships and collaborations.

What Are the Key Risks for LXRX?

Financial-distress signal — its Altman Z-Score of -3.85 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.6%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Sotagliflozin or LX9211.
• Regulatory setbacks in the approval process.
• Competition from established pharmaceutical companies.
• Dependence on partnerships for funding and development.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for LXRX?

• Expansion into New Therapeutic Areas: Lexicon can leverage its drug discovery platform to identify and develop novel therapies for additional disease areas beyond diabetes, heart failure, and neuropathic pain. This diversification can reduce risk and create new revenue streams. The market for novel therapeutics is constantly growing, with unmet needs in areas such as oncology, immunology, and rare diseases. Timeline: Ongoing, with potential for new drug candidates entering clinical trials within the next 2-3 years.
• Geographic Expansion: Lexicon can expand its commercial presence into new geographic markets, particularly in Asia and Europe, where there is growing demand for innovative therapies. Partnering with local distributors and establishing regional offices can facilitate market entry. The global pharmaceutical market is projected to reach $1.5 trillion by 2026. Timeline: 3-5 years, contingent on regulatory approvals and market access agreements.
• Strategic Partnerships and Acquisitions: Lexicon can pursue strategic partnerships and acquisitions to expand its pipeline, access new technologies, and enhance its commercial capabilities. Collaborating with other biotechnology companies and research institutions can accelerate drug development and reduce costs. The market for mergers and acquisitions in the biotechnology sector is robust, with numerous opportunities for value creation. Timeline: Ongoing, with potential for new deals within the next 1-2 years.
• Lifecycle Management of Sotagliflozin: Lexicon can extend the lifecycle of Sotagliflozin by developing new formulations, indications, and combination therapies. This can maximize the drug's revenue potential and maintain its competitive advantage. The market for diabetes and heart failure treatments is constantly evolving, with new innovations and treatment paradigms emerging. Timeline: Ongoing, with potential for new product launches within the next 3-5 years.
• Advancement of LX9211: Successful completion of Phase II clinical trials and subsequent Phase III development of LX9211 for neuropathic pain represents a significant growth opportunity. Positive clinical data and regulatory approval could establish LX9211 as a leading therapy in the pain management market. The neuropathic pain market is estimated to reach $8 billion by 2028. Timeline: 2-4 years, dependent on clinical trial outcomes and regulatory review.

What Are LXRX's Competitive Advantages?

• Proprietary drug discovery platform.
• Strong intellectual property protection for its drug candidates.
• Strategic partnerships with established pharmaceutical companies.
• Clinical data supporting the efficacy and safety of its products.

What Does LXRX Do?

Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas. The company is dedicated to discovering, developing, and commercializing innovative pharmaceutical products. Lexicon's primary focus is on orally-delivered small molecule drug candidates. Their lead drug candidate, Sotagliflozin, has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes. Sotagliflozin is designed to inhibit both SGLT1 and SGLT2, potentially offering benefits in glycemic control and cardiovascular outcomes. Another key asset in Lexicon's pipeline is LX9211, currently in Phase II clinical development for the treatment of neuropathic pain. LX9211 represents a novel approach to pain management. Lexicon has established strategic collaboration and license agreements with major pharmaceutical companies, including Bristol-Myers Squibb Company and Genentech, Inc., to support the development and commercialization of its drug candidates. These partnerships provide financial resources and expertise to advance Lexicon's pipeline. Lexicon continues to invest in research and development to expand its portfolio of innovative therapies.

What Products and Services Does LXRX Offer?

• Discovers and develops pharmaceutical products.
• Focuses on orally-delivered small molecule drugs.
• Develops Sotagliflozin for heart failure and type 1 diabetes.
• Develops LX9211 for neuropathic pain.
• Engages in strategic collaborations with pharmaceutical companies.
• Conducts clinical trials to evaluate drug efficacy and safety.
• Seeks regulatory approvals for its drug candidates.

How Does LXRX Make Money?

• Develops and patents novel pharmaceutical products.
• Out-licenses or co-develops products with larger pharmaceutical companies.
• Generates revenue through milestone payments and royalties from partnered products.

What Industry Does LXRX Operate In?

Lexicon Pharmaceuticals, Inc. operates within the biotechnology sector, a dynamic and competitive landscape characterized by rapid innovation and high regulatory hurdles. The market for diabetes and heart failure treatments is substantial, driven by increasing prevalence and an aging population. The neuropathic pain market also represents a significant opportunity. Competition comes from established pharmaceutical companies and other biotechnology firms developing novel therapies. Lexicon's success depends on its ability to secure regulatory approvals, demonstrate clinical efficacy, and effectively commercialize its products.

Who Are LXRX's Key Customers?

• Patients suffering from heart failure.
• Patients suffering from type 1 diabetes.
• Patients suffering from neuropathic pain.
• Pharmaceutical companies through collaborations and licensing agreements.

Over the past six months, Lexicon Pharmaceuticals, Inc. insiders filed 30 SEC Form 4 transactions — 8 sales and 22 purchases. On net that is roughly 20.9M shares acquired (about $490K) — insiders putting money in tends to read as conviction.

Lexicon Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 39.3% above estimates on average.

Lexicon Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.85 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Lexicon Pharmaceuticals, Inc. stands at -18.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.

Lexicon Pharmaceuticals, Inc. (LXRX) Valuation Context

Valued at $897M, LXRX is classified as a small-cap stock. Analyst price targets span from $6.00 to $6.00, with a consensus of $6.00. At the current price of $2.02, that implies approximately 197% upside potential. Relative to its peer group, LXRX's quantitative score of 13/100 is below the peer average of 84/100.

LXRX Revenue & Earnings Trend

In Q2 FY2026, LXRX generated $692K in top-line revenue, marking a sequential decrease of 96.7%. The company recorded a net loss of $31.8M, with diluted EPS of $-0.07. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, LXRX averaged $-0.04 in diluted EPS.

Company Profile

Lexicon Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in The Woodlands, US. The company is led by CEO Michael S. Exton. LXRX has traded publicly since 2000.

LXRX Financials

LXRX Latest News

LXRX Analyst Consensus

LXRX MoonshotScore

LXRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources